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ABSTRACT:
Dose selection during antiparasitic drug development in animal
models and humans traditionally has relied on correlations be-
tween plasma concentrations obtained at or below maximally tol-
erated doses that are efficacious. The objective of this study was
to improve the understanding of the relationship between dose and
plasma/tissue exposure of the model antiparasitic agent, pafura-
midine, using a semiphysiologically based pharmacokinetic (semi-
PBPK) modeling approach. Preclinical and clinical data generated
during the development of pafuramidine, a prodrug of the active
metabolite, furamidine, were used. A whole-body semi-PBPK
model for rats was developed based on a whole-liver PBPK model
using rat isolated perfused liver data. A whole-body semi-PBPK
model for humans was developed on the basis of the whole-body
rat model. Scaling factors were calculated using metabolic and
transport clearance data generated from rat and human sandwich-
cultured hepatocytes. Both whole-body models described pafura-
midine and furamidine disposition in plasma and predicted furami-
dine tissue (liver and kidney) exposure and excretion profiles
(biliary and renal). The whole-body models predicted that the in-
testine contributes significantly (30–40%) to presystemic furami-
dine formation in both rats and humans. The predicted terminal
elimination half-life of furamidine in plasma was 3- to 4-fold longer
than that of pafuramidine in rats (170 versus 47 h) and humans (64
versus 19 h). The dose-plasma/tissue exposure relationship for the
prodrug/active metabolite pair was determined using the whole-
body models. The human model proposed a dose regimen of
pafuramidine (40 mg once daily) based on a predefined efficacy-
safety index. A similar approach could be used to guide dose-
ranging studies in humans for next-in-class compounds.
Introduction
The primary goal of preclinical drug development is to identify
compounds with optimal efficacy and safety profiles and desirable
pharmacokinetic properties to advance to clinical trials. The design of
safe and effective dosage regimens that are compatible with the target
patient population and disease remains a major challenge. Suboptimal
dose selection can adversely influence progression of a drug devel-
opment program, resulting in additional time and expense for the
dose-ranging study (dose too low), or a poor understanding of risk/
benefit, causing unnecessary early termination of promising drug
candidates (dose too high).
Human African trypanosomiasis (HAT), a life-threatening parasitic
disease, affects the world’s poorest populations (Barrett, 2010). HAT
is characterized by a first stage, when parasites proliferate in the
hemolymphatic system, and a second stage, when parasites cross the
blood-brain barrier and invade the central nervous system. The disease
is fatal if untreated. All current chemotherapies are unsatisfactory
because of toxicity and/or inconvenient parenteral administration reg-
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imens (Barrett, 2010). Pafuramidine, a prodrug of furamidine, is the
only orally active agent that has shown efficacy in clinical trials for
treatment of first-stage infection (Paine et al., 2010). However, clin-
ical development of pafuramidine was placed on hold because of
transiently elevated liver transaminases observed in an expanded
phase I safety trial (http://www.immtechpharma.com/documents/
news_022208.pdf; Paine et al., 2010).
Bioconversion of pafuramidine to furamidine is believed to occur
primarily in the liver. The metabolic pathway involves sequential
oxidative and reductive reactions, producing four intermediate metab-
olites (Zhou et al., 2004). After a single oral dose of [14C]pafurami-
dine (10 mg/kg) to rats, tissue retention of total radioactivity, predom-
inantly as furamidine, was extensive (Midgley et al., 2007). The
highest concentration of radioactivity was detected in liver and was 3
orders of magnitude higher than that measured in plasma 24 h after
administration; radioactivity was still detectable in liver after 7 days.
Unlike with animal models, collection of liver tissue from human
subjects over a prolonged period of time is impossible for obvious
ethical reasons. As an alternative, a semiphysiologically based phar-
macokinetic (semi-PBPK) modeling approach could be used to pre-
dict the furamidine hepatic exposure-time profile in humans, permit-
ting improved understanding of the relationship between the dose of
pafuramidine and plasma/hepatic exposure of furamidine.
Hepatic clearance is a fundamental PBPK model parameter. Several
approaches have been developed to predict human hepatic clearance,
including 1) empirical allometric scaling, 2) physiologically based
direct scaling of in vitro human clearance, and 3) normalized scaling
of in vivo animal clearance based on in vitro animal and human data
(Luttringer et al., 2003; Ito and Houston, 2005). Empirical allometric
scaling, a conventional technique based on body weight, frequently
fails when drug disposition demonstrates large species differences
(Lavé et al., 1999). With physiologically based direct scaling, intrinsic
clearance, determined from human hepatocytes or liver microsomes,
is corrected by a physiologically based scaling factor, and subse-
quently scaled up on the basis of a liver model (well stirred or parallel
tube) (Ito and Houston, 2004). Although preferred to empirical allo-
metric scaling, physiologically based direct scaling consistently un-
derestimates human clearance because of decreased enzyme activity
or incomplete enzyme composition associated with in vitro systems
(Ito and Houston, 2005). Normalized scaling, via integration of in
vivo and in vitro data, represents an alternative approach to predict
human pharmacokinetics (Lave et al., 1997; Luttringer et al., 2003).
Application of these approaches has been limited primarily to the
estimation of metabolic clearance of parent compounds; interspecies
extrapolation of both metabolic and transport clearance values is
reported rarely for metabolites (Pang et al., 2008).
The objective of this study was to improve the understanding of the
relationship between pafuramidine dose and furamidine plasma/he-
patic exposure via a semi-PBPK modeling approach. First, a rat
whole-liver PBPK model was developed using rat isolated perfused
liver (IPL) data. Second, a whole-body semi-PBPK model for rats was
developed on the basis of the rat whole-liver PBPK model. Third,
normalized scaling was applied to rat IPL and rat and human sand-
wich-cultured hepatocyte data to predict the metabolic/transport clear-
ance of pafuramidine/furamidine in humans. Fourth, a whole-body
semi-PBPK model for humans was developed using the whole-body
rat semi-PBPK model and normalized scaling factors. The final
whole-body human model was used to predict furamidine plasma and
tissue exposure under various multiple-dose scenarios of pafurami-
dine. This approach could be used to guide dose-ranging human
studies for next-in-class compounds.
Materials and Methods
Materials and Chemicals. Dulbecco’s modified Eagle’s medium was pur-
chased from Invitrogen (Carlsbad, CA). ITS (insulin-transferrin-selenium)
culture supplement and Matrigel were obtained from BD Biosciences (San
Jose, CA). Penicillin, streptomycin, nonessential amino acids, dexamethasone,
Hanks’ balanced salt solution (HBSS), modified HBSS (HBSS without Ca2
and Mg2, with 0.38 g/l EGTA), and phosphate-buffered saline (PBS) were
purchased from Sigma-Aldrich (St. Louis, MO). Human plasma was obtained
from Biological Specialty Corporation (Colmar, PA). Pafuramidine, furami-
dine, and internal standards (d8-pafuramidine and d8-furamidine) were
synthesized in the laboratory of Dr. David W. Boykin (Georgia State
University, Atlanta, GA) as described previously (Boykin et al., 1996). All
other chemicals and reagents were of analytical grade and were used
without further purification.
Animals. Male Wistar and Sprague-Dawley rats (250–300 g) were pur-
chased from Charles River Laboratories (Raleigh, NC). Animals had free
access to water and food before surgery. All animal procedures were compliant
with guidelines of the University of North Carolina Institutional Animal Care
and Use Committee.
Disposition of Pafuramidine and Furamidine in IPLs from Rats. Data
were obtained from a previous recirculating rat IPL study, in which pafura-
midine was added as a bolus to the perfusate reservoir to yield an initial
concentration of 10 M (Yan et al., 2011). In brief, perfusions were conducted
ex vivo over designated times (up to 2 h) in a temperature-controlled chamber.
Aliquots of perfusate (400 l) were collected from the IPL reservoir at 5-min
intervals from 0 to 40 min and at 10-min intervals thereafter, and bile was
collected at 10-min intervals; the liver was harvested at the end of perfusion.
Determination of Unbound Fraction. The unbound fractions of furami-
dine in liver and perfusate from rat IPL experiments and rat plasma, deter-
mined using rapid equilibrium dialysis devices (Thermo Fisher Scientific,
Waltham, MA), were provided from a previous study (Yan et al., 2011). In the
present study, the unbound fractions of pafuramidine in liver and perfusate
from rat IPL experiments and rat plasma, as well as unbound fractions of
pafuramidine and furamidine in human plasma, were determined using the
same method. In brief, pafuramidine or furamidine was added to thawed rat
liver homogenates/perfusate/plasma to yield a concentration of 1 M. An
aliquot (200 l) and 0.1 M PBS (350 l) were placed in tissue and buffer
chambers, respectively, and incubated (37°C) on a Thermomixer (350 rpm)
(Eppendorf AG, Hamburg, Germany). After 6 h, aliquots (100 l) were
collected from the sample and buffer chambers and analyzed for total
(bound  unbound) and unbound pafuramidine or furamidine, respectively,
by LC-MS/MS.
Determination of Blood/Plasma Ratio in Rats. The blood/plasma (B/P)
ratios of pafuramidine and furamidine in rats were determined using an in vitro
method described previously (Berry et al., 2010). In brief, pafuramidine or
furamidine was added to prewarmed fresh rat blood and reference (blank)
plasma to yield a concentration of 0.1 M. After incubation at 37°C for 1 h in
a humidified and oxygenated incubator, compound-treated rat blood was
centrifuged at 1500g for 10 min, and plasma was separated from blood cells.
Plasma was analyzed for pafuramidine and furamidine by LC-MS/MS. The
B/P ratios were calculated by dividing the peak area observed in the reference
plasma (representing nominal blood concentration) by the peak area observed
in the compound-treated plasma (representing plasma concentration).
Disposition of Pafuramidine and Furamidine in Rat and Human Sand-
wich-Cultured Hepatocytes. Rat sandwich-cultured hepatocyte (SCH) data
were obtained from a previous study (Yan et al., 2011). Freshly isolated
suspended human hepatocytes, provided by Invitrogen, were seeded at 1.5 
106 cells/well onto 6-well plates and overlaid with Matrigel in the same
manner as described for rat hepatocytes (Yan et al., 2011). The liver donors
were reported as white (two women and one man; 50, 56, and 57 years old,
respectively). Culture medium [Dulbecco’s modified Eagle’s medium supple-
mented with 1% (v/v) ITS, 1 M dexamethasone, 2 mM L-glutamine, 1%
(v/v) nonessential amino acids, 100 units penicillin G sodium, and 100 g/ml
streptomycin sulfate] was changed daily for 5–7 days until extensive canalic-
ular networks were formed. On the day of experimentation, SCH were incu-
bated with culture medium (1.5 ml) containing pafuramidine at the same
concentration (10 M) as that used in rat SCH experiments (Yan et al., 2011).
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At designated times up to 24 h, aliquots of medium (500 l) were collected,
and cells were washed twice and incubated at 37°C for 5 min with 2 ml of
standard HBSS (to maintain bile canalicular networks; cells  bile) or Ca2-
free HBSS (to open bile canalicular spaces; cells) (Turncliff et al., 2006). After
incubation, buffer was removed, and cells were washed three times with 2 ml
of ice-cold standard HBSS and lysed with 1 ml of ice-cold methanol-water
(7:1, v/v) containing 0.1% (v/v) trifluoroacetic acid (TFA). Media and cell
lysates were stored at 80°C pending analysis for pafuramidine and furami-
dine by LC-MS/MS.
In Vivo Studies. Rats. Data were provided from a previous study, in which
four Sprague-Dawley rats were administered a single dose of pafuramidine
(7.5 mol/kg) by oral gavage (Generaux, 2010). Pafuramidine was prepared as
a suspension in acidified water (pH 3)-70% Tween 80 in ethanol (7:3, v/v).
Blood (0.2 ml) was collected via a jugular vein cannula over 24 h after
pafuramidine administration. Plasma was separated from blood cells by cen-
trifugation (1500g for 10 min) and analyzed for pafuramidine and furamidine
by LC-MS/MS (see below).
Humans. A phase I, open-label study was conducted by Hammersmith
Medicines Research (London, UK). The primary objective was to assess the
absorption, metabolism, and excretion of [14C]pafuramidine maleate in healthy
male volunteers. The Medicines and Healthcare Products Regulatory Agency,
Administration of Radioactive Substances Advisory Committee, and Hunting-
don Research Ethics Committee reviewed the study protocol; the Brent Med-
ical Ethics Committee conducted a site-specific assessment of the study. The
study commenced upon authorization by the Medicines and Healthcare Prod-
ucts Regulatory Agency and approval by the Administration of Radioactive
Substances Advisory Committee and ethics committees. Potentially eligible
subjects provided written, informed consent before screening, which entailed a
medical history, physical examination, vital signs (blood pressure and heart
rate), 12-lead electrocardiogram (ECG), standard blood and urine laboratory
analyses, and breath tests for alcohol and smoking (carbon monoxide). Exclu-
sion criteria included radiation exposure (a radioactive substance or X-rays,
with the exception of dental X-rays or X-rays of the chest, hands, or feet)
during the 12 months before the study; abnormal history or physical observa-
tions, ECG, or laboratory values that could interfere with the study objectives
or safety of the volunteer; acute or chronic illness that could preclude or render
hazardous the volunteer’s participation; severe adverse reaction to any drug or
a history of sensitivity to dicationic compounds; prescription medication use
during the 28 days before the study or use of over-the-counter preparations,
including herbal/dietary supplements, during the 7 days before the study;
presence or history of drug or alcohol abuse; tobacco product use within the
previous 6 months; and blood pressure and heart rate in the seated position
outside the ranges of 90 to 160 mm Hg systolic/40 to 95 mm Hg diastolic and
40 to 100 beats/min, respectively.
Healthy male white volunteers (n  6), aged from 48 to 63 years and
weighing from 63 to 108 kg, were enrolled in the study. All subjects reported
to the hospital ward at 8:00 PM the evening of day 1 (the day before drug
administration); urine was collected and tested for drugs of abuse, and breath
was collected and tested for alcohol and smoking (carbon monoxide). After an
overnight fast, a cannula was placed into an antecubital vein the next morning
(day 1), and the following were undertaken within 60 min before drug
administration: 12-lead ECG; measurement of vital signs; venous blood col-
lection for laboratory safety tests and baseline radioactivity measurement; and
urine collection for laboratory safety tests. Subjects finished eating a high-fat
breakfast (2 eggs fried in butter, 2 bacon strips fried in butter, 2 slices of
buttered toast, 4 ounces of hash brown potatoes, and 8 fluid ounces of whole
milk), approximately 15 min before dosing to facilitate drug absorption.
Each volunteer was administered a single oral dose of [14C]pafuramidine
maleate (nominal dose 131.9 mg, equivalent to 100 mg of pafuramidine free
base) with 100 ml of water between 9:00 and 9:25 AM. The dose was prepared
in capsule form and contained 0.7 MBq (19 Ci) of radioactivity. The dose of
pafuramidine free base was consistent with clinical use of the drug; the dose of
radioactivity was consistent with the upper limit for a category IIa study set by
the International Commission of Radiological Protection for trials in male
volunteers. After [14C]pafuramidine administration, blood was collected at
designated times from 0.5 to 168 h; vital signs and 12-lead ECGs were
recorded from 1 to 168 h; urine was collected continuously in 3-, 6-, 12-, and
24-h intervals from 0 to 168 h; and feces were collected as individual evacu-
ations from 0 to 168 h. Within 30 min of blood collection, plasma was
separated from blood cells by centrifugation (700–1500g for 10 min). Whole
blood and the resultant plasma, as well as urine and feces, were stored at
20°C pending analysis for total radioactivity, pafuramidine, and furamidine.
Approximately 168 h after drug administration, blood and urine were collected
for laboratory safety tests, and a physical examination was conducted. Other
than the high-fat breakfast on day 1, standard meals and beverages were
provided to the subjects during their stay on the ward. Alcoholic and
caffeinated beverages, grapefruit and grapefruit juice, smoking, and stren-
uous exercise were not allowed from 24 h before drug administration until
after discharge.
Subjects were discharged on the morning of day 8 (168 h after drug
administration). They returned to the ward as outpatients to provide complete
urine and fecal collections from the previous 24 h. These outpatient visits,
planned on the mornings of days 10, 14, 21, 28, 35, and 42, continued until
there was no measurable radioactivity in urine and feces. At each visit, vital
signs and 12-lead ECGs were recorded and a physical examination was
conducted.
Total radioactivity was measured in whole blood, plasma, urine, and feces
by high-performance liquid radiochromatography. Pafuramidine and furami-
dine concentrations in plasma were measured by LC-MS/MS (see below).
LC-MS/MS Analysis. In vitro samples and rat plasma. Pafuramidine and
furamidine were quantified using an API 4000 triple quadrupole mass spec-
trometer (Applied Biosystems, Foster City, CA) equipped with a TurboIonSpray
interface (Applied Biosystems/MDS Sciex, Foster City, CA). The sample
preparation procedure and LC-MS/MS conditions for the quantification of
pafuramidine and furamidine were detailed previously (Yan et al., 2011). In
brief, pafuramidine and furamidine and internal standards (d8-pafuramidine
and d8-furamidine) were separated on an Aquasil C18 HPLC column (2.1
mm  50 mm, 5 m) (Thermo Fisher Scientific) with a high-pressure linear
gradient program. Calibration curves were prepared in appropriate matrices
(0.05–5 M in liver homogenates; 1–10,000 nM in perfusate, medium, cell
lysates, human plasma, and PBS) and were linear over the respective ranges
(R2  0.98). The limit of quantification was 5 nM for both compounds.
Human plasma. Quantification of pafuramidine and furamidine was con-
ducted by Tandem Labs (Salt Lake City, UT). The stock solutions of analytes
(pafuramidine and furamidine) and internal standards (d8-pafuramidine and
d8-furamidine) were prepared in 100% methanol to yield concentrations of
0.37, 0.41, 0.21, and 0.3 mg/ml, respectively. Stock solutions of pafuramidine
and furamidine were diluted in blank human plasma to yield working concen-
trations of 5000 and 2000 ng/ml for preparation of calibration standards and
quality controls, respectively. Calibration standards (0.25–250 ng/ml) and
quality controls (0.75, 75, and 200 ng/ml) for pafuramidine and furamidine
were prepared by serial dilution of each working solution with blank human
plasma. The working internal standard solutions (100 ng/ml d8-pafuramidine
and d8-furamidine) were prepared by diluting the respective stock solution
with 0.05% TFA in water-methanol (5:5, v/v); 50 l of the diluted stock
solution and 500 l of 50 nM ammonium acetate buffer (pH 3) were added to
100 l of human plasma, standards, and quality controls. After vortex mixing,
all samples were loaded onto Polycrom B1000 1cc, 20-mg extraction car-
tridges (Cera, Inc., Baldwin Park, CA), followed by serial washing of the solid
phase with 300 l of 50 mM ammonium acetate buffer (pH 3), followed by
300 l of 50 mM ammonium acetate buffer (pH 3)-methanol (8:2, v/v).
Analytes were eluted with 300 l of acetonitrile, followed by 300 l of 0.1%
hydrochloric acid in methanol. After evaporation at 45°C (TurboVap; Zymark
Corp., Hopkinton, MA), samples were reconstituted with 50 l of 0.05% TFA
in water-acetonitrile (9:1; v/v) and transferred to HPLC vials. Pafuramidine
and furamidine were quantified on an API 3000 triple quadrupole mass
spectrometer (PE Sciex, Concord, ON, Canada). Analytes were separated on a
BDS Hypersil Phenyl HPLC column (2 mm  50 mm, 5 m) at 35°C with a
high-pressure linear gradient program consisting of 0.05% TFA in HPLC-
grade water (A) and HPLC-grade acetonitrile (B) delivered by a HP 1100
pumping system (Hewlett Packard, Palo Alto, CA) at a flow rate of 300
l/min. Mobile phase composition was increased from 10 to 70% B from 0 to
3.5 min and then decreased to 10% B from 3.5 to 3.6 min; the column was
reequilibrated for 2 min before the next injection. Calibration curves for
pafuramidine and furamidine were linear from 0.25 to 250 ng/ml (R2  0.99).
Intra- and interday precision (expressed as coefficient of variation percentage)
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and accuracy (expressed as bias percentage) of quality controls for both
compounds were 15%. The mass spectrometers were operated in positive ion
mode using multiple reaction monitoring: pafuramidine, 365.1 3 334.1 m/z;
furamidine, 305.3 3 288.1 m/z; d8-pafuramidine, 373.1 3 242.0 m/z; d8-
furamidine, 313.3 3 296.1 m/z.
Semi-PBPK Modeling: Model Approach. Kinetic parameters associated
with hepatic disposition of pafuramidine and furamidine were generated from
the whole-liver semi-PBPK model and used to develop the whole-body rat
semi-PBPK model. Preclinical data on preformed furamidine kidney-to-plasma
partitioning and renal excretion were incorporated to predict formed furami-
dine disposition in rats. In vivo rat data were used to develop the semi-PBPK
model structure and associated parameters. Kinetic parameters for humans (see
Semi-PBPK Modeling: Model Parameterization) were used to predict the
disposition of pafuramidine and furamidine and, ultimately, to predict the
relationship between dose and plasma or tissue exposure.
Semi-PBPK Modeling: Model Structure. Rat whole liver. Pafuramidine
and furamidine submodels were linked by pafuramidine metabolism in the
liver (Fig. 1A). The pafuramidine submodel for rat IPLs was composed of two
compartments: perfusate reservoir and liver (Fig. 1A). The furamidine sub-
model was composed of three compartments: perfusate reservoir, liver, and
bile. Pafuramidine is highly lipophilic (log DpH_7  4.3) (Zhou et al., 2002)
and poorly soluble, qualifying as a class II compound according to the
Biopharmaceutics Classification System (Wu and Benet, 2005). As such,
pafuramidine was assumed to diffuse passively through the hepatic basolateral
membrane. In contrast to pafuramidine, furamidine is hydrophilic (log DpH_7  3)
(Zhou et al., 2002). Furamidine basolateral reuptake and efflux clearances
(ClF_up, u and ClF_eff, u) (Table 1) estimated by the whole-liver model (Fig. 1A)
were at least 2-fold lower than the perfusate flow rate (4 l  h1  kg1),
suggesting that diffusional barriers exist for furamidine. Therefore, distribution
of pafuramidine and furamidine in the liver was assumed to be flow- and
diffusion-limited, respectively (Fig. 1A).
Rat whole body. The whole-liver rat model was expanded into a whole-body
rat model by substituting the perfusion reservoir with the blood compartment
(Fig. 1B). On the basis of the high lipophilicity of pafuramidine, fat was added
as a storage organ in the pafuramidine submodel. The kidney was incorporated
as an additional storage organ in the furamidine submodel on the basis of the
significant kidney retention of furamidine (Midgley et al., 2007; Goldsmith,
2011); all other tissues were grouped together as “rest of body” in both
submodels to maintain mass balance (Fig. 1B). Pafuramidine distribution into
the liver was assumed to be flow-limited, whereas furamidine distribution into
the liver was assumed to be diffusion-limited. To avoid overparameterization,
distribution of both compounds into all other organs was assumed to be
flow-limited (Fig. 1B). On the basis of the high hepatic extraction ratio
calculated from IPL data (EH  0.88) (Yan et al., 2011), pafuramidine was
assumed to be cleared from the body primarily via hepatic metabolism. On
the basis of in vivo data, furamidine was assumed to be eliminated via both
biliary and renal excretion (Midgley et al., 2007; Goldsmith, 2011). To
simulate pafuramidine and furamidine plasma concentration-time profiles,
the model incorporated a single gut compartment for pafuramidine absorp-
tion after oral administration. Absorption of pafuramidine from gut to liver
was assumed to be a first-order process. Because the initial model failed to
describe the prompt appearance of furamidine in plasma, the model was
modified to include the gut as a site of furamidine formation during
pafuramidine absorption.
Human whole body. The final whole-body rat model was used initially to
predict the disposition of pafuramidine/furamidine in humans. However,
model predictions failed to describe the delayed absorption of pafuramidine
observed in humans, which may be attributed to the capsule formulation,
concurrent administration of a high-fat meal, and/or species differences in gut
metabolism and/or transport. Therefore, three consecutive transit compart-
ments were added between the site of administration (oral route) and site of
absorption (gut) in the pafuramidine submodel (Fig. 1B) to represent dissolu-
tion from the dosage form (capsule), stomach emptying, and/or partitioning
from the fat components of the concomitant high-fat meal. Species differences
in gut metabolism and/or transport were considered as described under Semi-
PBPK Modeling: Model Parameterization.
Semi-PBPK Modeling: Model Parameterization. Absorption and metab-
olism in the gut. Absorption and metabolism of pafuramidine/furamidine in the
gut have not been characterized extensively in rats and humans. Thus, the
relevant kinetic parameters, including the fraction of the dose absorbed into
enterocytes (fa), the rate constants associated with absorption of pafuramidine
or furamidine (ka_P or ka_F), and the rate constant associated with metabolic
conversion from pafuramidine to furamidine in the gut (kG_P3F) were esti-
mated by fitting the semi-PBPK models (Fig. 1B) to in vivo rat and human
data.
Tissue distribution. Tissue-to-perfusate/plasma partition coefficients
were optimized by fitting relevant PBPK models (Fig. 1, A and B) to IPL
and in vivo rat data. The pafuramidine liver-to-plasma partition coefficient
in rats was calculated on the basis of the liver-to-perfusate partition
coefficient generated from the rat IPL data after correction for the 5-fold
difference in unbound fraction between plasma and perfusate (Table 1).
FIG. 1. Semi-PBPK model schemes depicting disposition of pafuramidine and
furamidine in rat IPLs (A) and in vivo in rats and humans (B). Distinct model
structures were developed for the prodrug, pafuramidine, and the derived active
metabolite, furamidine, and linked by liver (and gut) metabolism. Pafuramidine
distribution in all tissue compartments was assumed to be flow-limited. Furamidine
distribution in the liver was described as diffusion-limited, as depicted by the dashed
line in the liver compartment; furamidine distribution in all other tissue compart-
ments was assumed to be flow-limited. Compartments T1, T2, and T3 in the dashed
square represent three consecutive transit compartments for pafuramidine before
reaching the absorption site in the gut after oral administration in humans, where
kP_12, kP_23, and kP_3g represent the first-order rate constants for pafuramidine
distribution along the transit compartments and gut. kG_P3F represents the first-
order rate constant for metabolic conversion from pafuramidine to furamidine in the
gut; ka_P and ka_F represent the first-order rate constants for the movement from gut
to liver of pafuramidine and formed furamidine, respectively. ClL_P3F, u represents
hepatic unbound intrinsic clearance for the formation of furamidine from pafura-
midine; ClL_P3M, u represents hepatic unbound intrinsic clearance for metabolic
conversion from pafuramidine to other metabolites; ClF_up, u represents unbound
intrinsic clearance for hepatic basolateral uptake of furamidine, ClF_eff, u represents
unbound intrinsic clearance for hepatic basolateral efflux of furamidine, ClF_bile, u
represents unbound intrinsic clearance for biliary excretion of furamidine, and
ClF_renal, u represents unbound renal clearance of furamidine from plasma. P, pa-
furamidine; M, other metabolites; F, furamidine.
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Because of the lack of human tissue data, tissue partition coefficients and
liver binding for pafuramidine/furamidine in humans were assumed to be
equal to those in rats (Table 1).
Hepatic clearance. Rat hepatic clearance (Clrat_liver) values were derived by
fitting the whole-liver rat model to the rat IPL data. Clrat_liver, which repre-
sented metabolic and/or active transport capacities, was normalized by a
scaling factor (SF) and corrected for liver weight (LW) to estimate the human
hepatic clearance value: Clhuman_liver  Clrat_liver  SF  (LWhuman/LWrat),
where SF is Clhuman SCH/Clrat SCH or khuman SCH/krat SCH and LWhuman and LWrat
were normalized to body weight for humans and rats, respectively. Because
biliary Cl of formed furamidine was too small to measure in either rat or
human SCH, in vivo human biliary Cl was estimated by scaling in vivo rat
biliary Cl on the basis of liver weight.
Renal clearance. Furamidine unbound renal clearance from plasma in rat
(ClR_rat, u) was calculated on the basis of preclinical data in rats administered
furamidine intravenously (10 mol/kg) (Goldsmith, 2011). In brief, rats (n 
3–7) were sacrificed at designated time points up to 16 days after furamidine
administration, after which kidneys were harvested and homogenized; urine
was collected at 0 to 3, 3 to 6, 6 to 12, and 12 to 24 h intervals after furamidine
administration. ClR_rat, u was calculated by dividing the total amount of fura-
midine recovered in urine from 0 to 24 h by the area under the concentration-
time curve (AUC) in plasma within the same time interval and was corrected
TABLE 1






Body weight (kg) 0.3 70 Measured
Cardiac output (l  h1  kg1) 14 5 Brown et al., 1997
Blood and tissue volumesa
Blood 0.074 0.077 Brown et al., 1997
Fat 0.07 0.2 Brown et al., 1997
Liver 0.03 0.03 Brown et al., 1997
Kidney 0.007 0.004 Brown et al., 1997
Tissue blood flowsa
Fat 0.07 0.05 Brown et al., 1997
Liver 0.17 0.25 Brown et al., 1997
Kidney 0.14 0.19 Brown et al., 1997





b 0.07  0.02 Same as rats Measured
Perfusate (fu, per_P) 1.1  0.1 N.A. Measured
Plasma (fu, p_P) 0.2  0.02 0.2  0.01 Measured
Liver-to-perfusate partition coefficient 70 N.A. Fitted
Tissue-to-plasma partition coefficients
Liver 14 Same as rats Calculated
Fat 260 Same as rats Fitted
Rest of body 2 Same as rats Fitted
B/P ratioc 1.1  0.1 Same as rats Measured
Fraction of dose absorbed into enterocytes (fa) 0.3 1 Fitted
Gastrointestinal rate constants (h1)d
kP_12, kP_23, kP_3g N.A. 1.1 Fitted
ka_P 0.5 1.1 Fitted
kG_P3F 0.07 0.3 Fitted
Hepatic clearance (l  h1  kg b.wt.1)e
ClL_P3M, u 70 124 Fitted (rat); scaled (human)




b 0.3  0.1 Same as rats Measured
Perfusate (fu, per_F) 44  5 N.A. Measured
Plasma (fu, p_F) 24  2 25  3 Measured
Tissue-to-plasma partition coefficients
Kidney 4000 Same as rats Fitted
Rest of body 1 Same as rats Fitted
B/P ratioc 0.9  0.1 Same as rats Measured
Gastrointestinal rate constants (h1)d
ka_F 2.4 0.2 Fitted
Hepatic and renal clearances (l  h1  kg b.wt.1)e
ClF_up, u 1.9 1 Fitted (rat); scaled (human)
ClF_eff, u 0.08 0.05 Fitted (rat); scaled (human)
ClF_bile, u 0.08 0.05 Fitted (rat); scaled (human)
ClF_renal, u 0.12 0.024 Calculated
GFRf 0.4 0.08 Lin, 1998
N.A., not applicable.
a Tissue volumes and blood flows denote fractions of total body weight and cardiac output, respectively.
b Liver unbound fractions in humans were assumed to be equal to those in rats.
c B/P ratio of pafuramidine or furamidine at 0.1 M in rat blood (see Materials and Methods).
d Rate constants associated with pafuramidine and furamidine absorption and metabolism in the gut are defined in the legend to Fig. 1 and were optimized by fitting the semi-PBPK model (scheme
depicted in Fig. 1B) to in vivo rat and human data.
e Clearance values associated with the disposition of both pafuramidine and furamidine in rat livers are defined in the legend to Fig. 1 and were optimized by fitting the semi-PBPK model (scheme
depicted in Fig. 1A) to rat IPL data, corresponding hepatic clearances in humans were calculated as described under Materials and Methods, furamidine renal clearance in rats was calculated on
the basis of in vivo rat data, and human renal clearance was estimated using a “GFR ratio approach” proposed by Lin (1998) (see Materials and Methods).
f GFR was obtained from Lin (1998).
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by the unbound fraction of furamidine in plasma (Table 1). The unbound renal
clearance of furamidine from plasma in humans (ClR_human, u; liters per hour
per kilogram) was estimated by the “glomerular filtration rate (GFR) ratio
approach” (Lin, 1998), assuming that active processes were not involved:
ClR_human, u  ClR_rat, u/GFR ratio, where the GFR ratio between rats and
humans is 4.8.
PBPK Modeling and Simulation. Pharmacokinetic analysis. PBPK mod-
eling and simulation were performed with Berkeley Madonna (version 8.0.2;
University of California, Berkeley, CA), a differential equation-based model-
ing software program used extensively in the development of PBPK models
(Rowland et al., 2004). The goodness-of-fit of model simulations was assessed
on the basis of a visual comparison of the predicted mass/concentration-time
profiles and observed in in vivo rat and human data. Observed and predicted
plasma/tissue concentration-time profiles were analyzed for plasma/tissue
AUC values and terminal half-lives (t1/2, terminal) of pafuramidine/furamidine
by noncompartmental analysis using WinNonlin (version 5.0.1; Pharsight,
Mountain View, CA).
Prediction of dose-exposure relationship. Furamidine plasma concentra-
tion-time profiles were simulated under different multiple-dose regimens on
the basis of the single-dose human semi-PBPK model (Fig. 1B). The efficacy
and safety indices of furamidine were defined by a minimum effective con-
centration (Ceff, min) and a hypothetical no observable adverse effect level
(NOAEL), respectively. Selection of an optimal multiple-dose regimen of
pafuramidine was based on the assumption that furamidine concentrations in
plasma must be greater than Ceff, min at least 80% of the time during the dosing
interval, whereas the average steady-state and maximum concentrations in
plasma (Css, ave and Css, max) must be less than the NOAEL. Ceff, min was
determined on the basis of an in vitro IC50 (1 ng/ml 	 3 nM) of furamidine
against the Trypanosoma brucei rhodesiense strain, STIB900 (Wenzler et al.,
2009). This trypanosome strain is used routinely at the Swiss Tropical and
Public Health Institute to assess in vitro and in vivo activity of diamidine
compounds (Ismail et al., 2005). The IC50, determined with culture medium
containing 15% heat-inactivated horse serum, was converted to Ceff, min on the
basis of the following assumptions: 1) no species differences in plasma binding
(fu, p_F  25%) (Table 1); and 2) binding in 15% horse serum (fu, ser_F)
approximated that in rat perfusate (fu, per_F), which consisted of 20% rat blood;
that is, fu, ser_F  fu, per_F  44% (Table 1). Ceff, min for total (bound 
unbound) furamidine in plasma was corrected to 5 nM (Ceff, min  IC50 
fu, ser_F/fu, p_F  3 nM  44%/25%  5 nM). The NOAEL has not been
determined for furamidine in humans. A concentration of 100 nM, which is
20% less than the predicted Css, ave under the dosage regimen used in the
expanded phase I safety study (100 mg twice daily for 14 days), was selected
to define the NOAEL. Dose safety was evaluated by comparing the furamidine
concentrations in plasma with the hypothetical NOAEL and comparing fura-
midine exposure in liver between the clinically used and semi-PBPK model-
predicted dosage regimens.
Results
Whole-Liver Rat PBPK Model Prediction. The disposition of
pafuramidine and furamidine in rat IPLs was characterized in a
previous study (Yan et al., 2011). In summary, pafuramidine was
taken up by IPLs and eliminated primarily by metabolism, with
negligible biliary excretion; at the end of the 2-h perfusion, 98% of
total formed furamidine was recovered in the liver. Pafuramidine
distribution between perfusate and liver reached equilibrium after
20 min. The liver-to-perfusate partition coefficient for pafurami-
dine, generated on the basis of the whole-liver model (Fig. 1A), was
70 (Table 1). Pafuramidine was highly bound to proteins in plasma,
perfusate (composed of 20% blood), and liver tissue (Table 1),
whereas furamidine was highly bound only to liver tissue. The un-
bound fraction of furamidine in liver (fu, L_F) was at least 80-fold
lower than that in plasma (fu, p_F) and perfusate (fu, per_F) (Table 1).
Hepatic unbound intrinsic formation clearance of furamidine
(ClL_P3F, u) accounted for approximately one-third of total hepatic
unbound intrinsic clearance of pafuramidine (ClL_P3F, u 
ClL_P3M, u) (Table 1). The unbound intrinsic clearance for furami-
dine hepatic basolateral reuptake (ClF_up, u) was 24-fold higher than
that for basolateral efflux (ClF_eff, u) (Table 1), whereas the unbound
intrinsic clearance for furamidine biliary excretion (ClF_bile, u) was
similar to that of ClF_eff, u (Table 1).
Disposition of Pafuramidine and Furamidine in Rat and Hu-
man Sandwich-Cultured Hepatocytes. The disappearance of pafura-
midine from medium was faster in human than in rat SCH (Fig. 2), as
reflected by the 3-fold higher intrinsic clearance of pafuramidine in
human than in rat SCH (Table 2). Disposition profiles of formed
furamidine were similar between rat and human SCH (Fig. 2). The
kinetic parameters associated with pafuramidine and furamidine he-
patic disposition in rat and human SCH were derived from a previ-
ously developed compartmental model (Yan et al., 2011). The rate
constants for furamidine basolateral efflux were similar between rats
and humans, whereas the rate constant for furamidine basolateral
reuptake in human SCH was three-fourths of that in rat SCH (Table
2). Furamidine was not detected in bile in either rat or human SCH,
which could be due to the fact that biliary excretion of furamidine was
so small that the difference in substrate accumulation between stan-
dard HBSS (cells  bile) and Ca2-free HBSS (cells) was not
measurable (Yan et al., 2011).
Disposition of Pafuramidine and Furamidine in Rats. Pafurami-
dine was absorbed and metabolized to furamidine rapidly after oral
administration; both compounds in plasma reached a maximum con-
FIG. 2. Disposition of pafuramidine () and furamidine (Œ) over 24 h in SCH from
rats (A) and humans (B). Rat SCH data were obtained from a previous study (Yan
et al., 2011); human SCH data were obtained using a similar study design. Pafura-
midine (10 M) was administered as a bolus to each well, which contained 1.5 ml
of culture medium. Symbols and error bars denote mean values and SDs, respec-
tively of n  3 livers. Lines represent the computer-generated best fit of a previously
developed pharmacokinetic model (Yan et al., 2011) to the data.
11SEMI-PBPK MODELING TO PREDICT PRODRUG/METABOLITE EXPOSURE
centration at 1 h and declined approximately in parallel for up to
12 h (Fig. 3A, inset). The apparent terminal half-life (t1/2, app) of
pafuramidine, based on the 0 to 12 h plasma concentration-time
profile, was similar to that of furamidine (4 h).
Whole-Body Rat Semi-PBPK Model Prediction. Physiological
and pafuramidine- and furamidine-specific parameters (Table 1) were
used to develop the rat semi-PBPK model (Fig. 1B). Pafuramidine and
furamidine hepatic disposition parameters were obtained from the rat
whole-liver model (Fig. 1A). The partition coefficient of pafuramidine
in fat was much higher than that in other tissues, which could be due
to the high lipophilicity (Zhou et al., 2002; Andersen et al., 2008). On
the basis of previous data from rats administered preformed furami-
dine intravenously (Goldsmith, 2011), the furamidine kidney-to-
plasma partition coefficient was estimated to be as high as 4000
(Table 1); the renal clearance of furamidine from plasma (ClF_renal, u)
in rats was approximately 3-fold less than the GFR (Table 1) (Gold-
smith, 2011). The rate constant for pafuramidine absorption (ka_P) was
7-fold higher than that for metabolic conversion of pafuramidine to
furamidine in the gut (kG_P3F). The overall fraction of furamidine
formed from pafuramidine in the rat was approximately 40%, of
which the liver contributed approximately twice as much as the gut
(Table 3). The semi-PBPK model (Fig. 1B) adequately described
pafuramidine/furamidine disposition observed in plasma up to 12 h
(Fig. 3A, inset). On the basis of model predictions through 360 h, the
t1/2, terminal values of both pafuramidine and furamidine were at least
10-fold longer than those measured from the 0 to 12 h observed in
vivo data (t1/2, app); t1/2, terminal of furamidine was 4-fold longer than
that of pafuramidine (170 versus 47 h) (Fig. 3A). The semi-PBPK
model predicted that liver and kidney accumulation of furamidine was
extensive, accounting for 63 and 32% of the total formed at 12 h,
respectively; 1% of furamidine was recovered in plasma at 12 h.
Furamidine exposure in liver and kidney reached a maximum at 24
h (Fig. 3B) and then declined in parallel with that in plasma (Fig. 3A).
Furamidine was eliminated in rat primarily by biliary excretion; renal
excretion was 10% (Table 3; Fig. 3B).
Disposition of Total Radioactivity, Pafuramidine, and Furami-
dine in Humans. All of the volunteers completed the study. All
subjects reported 11 adverse events (3 moderate and 8 mild) after
[14C]pafuramidine administration, the most common of which was
headache. Only two events (mild headache) were considered to be
possibly related to the study medication. There were no changes in
vital signs, 12-lead ECG, or laboratory values that were clinically
significant or that could reasonably be attributed to the study medi-
cation. Overall, a single oral dose of [14C]pafuramidine maleate was
deemed safe and well tolerated.
Total radioactivity in whole blood was only measurable from 3 to
5 h after [14C]pafuramidine maleate administration. Maximum radio-
activity concentrations in whole blood ranged between 490 and 890
ng equivalents/ml (mean Cmax  570 ng equivalents/ml), and Tmax
ranged from 2 to 4 h (median  3 h). Total radioactivity in plasma
was consistently measurable from 2.5 to 12 h; maximum radioactivity
concentrations ranged between 650 and 980 ng equivalents/ml (mean
Cmax  760 ng equivalents/ml), and Tmax ranged from 2 to 5 h
(median  4.5 h). Radioactivity concentrations in whole blood were
generally lower than corresponding concentrations in plasma.
FIG. 3. Disposition of pafuramidine () and furamidine (Œ) in rats administered a
single oral dose of pafuramidine (7.5 mol/kg). A, comparison of observed (sym-
bols) and semi-PBPK model-predicted (scheme depicted in Fig. 1B) (lines) plasma
concentration-time profiles of pafuramidine and furamidine over 12 h (inset) and
360 h. Symbols and error bars denote mean values and SD, respectively, of four rats.
B, semi-PBPK model-predicted (scheme depicted in Fig. 1B) amount-time profiles
of furamidine in liver/kidney (solid lines) and bile/urine (dashed lines) over 360 h.
TABLE 2
Kinetic parameters associated with disposition of pafuramidine and furamidine
in rat and human SCH
Parametera Rat SCH Human SCH Scaling Factorb
ClL_P3M (ml  min
1  106 cells1) 0.0047 0.013 3
ClL_P3F (ml  min
1  106 cells1) 0.0023 0.0067 3
kF_up (h
1) 0.8 0.6 0.75
kF_eff (h
1) 0.008 0.008 1
kF_bile (h
1)c N.A. N.A. N.A.
N.A., not applicable.
a ClL_P3M and ClL_P3F represent in vitro intrinsic clearance for the metabolic conversion of
pafuramidine to other metabolites and furamidine, respectively. kF_up, kF_eff, and kF_bile represent
first-order rate constants for furamidine hepatic basolateral uptake, efflux and biliary excretion,
respectively. SCH values denote mean data from n  3 separate livers.
b Determined by the ratio of human to rat hepatic clearances or rate constants determined with
SCH. The scaling factor was used to normalize in vivo clearance values from rats before scaling
to human clearance values (see Materials and Methods).
c Furamidine biliary excretion was undetectable in both rat and human SCH.
TABLE 3
Semi-PBPK model prediction of furamidine presystemic formation and excretion
in rats and humans after administration of a single oral dose of pafuramidine







Presystemic formation in gutb 30 40
Presystemic formation in liverb 70 60
Excretion into bilec 93 96
Excretion into urinec 7 4
a Total fraction of pafuramidine converted to furamidine.
b Contribution of gut or liver to furamidine presystemic formation.
c Calculated based on the cumulative amount of furamidine excreted in bile or urine, relative
to total excreted, to infinite time.
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After [14C]pafuramidine maleate administration, pafuramidine was
measurable in plasma by 0.5 h in five of the six subjects. Pafuramidine
plasma concentrations increased to a maximum value ranging be-
tween 98 and 644 nM (mean Cmax  186 nM) from 1.5 to 4 h (median
Tmax  2.8 h). Pafuramidine plasma concentrations declined, with a
t1/2, app ranging from 4 to 46 h (harmonic mean  11.5 h). Furamidine
was not consistently measurable in plasma until 2 h after [14C]pafura-
midine administration and increased to a maximum concentration
ranging between 39 and 114 nM (mean Cmax  44 nM) from 4 to 10 h
(median Tmax  6 h). Furamidine plasma concentrations declined,
with a t1/2, app ranging from 8 to 42 h (harmonic mean  14.5 h).
Both pafuramidine and furamidine were above the limit of quantifi-
cation in plasma of all subjects up to 24 h after drug administration.
Within 168 h of [14C]pafuramidine administration (during which
complete collections of excreta were available), the major route of
elimination of radioactivity was via the feces. The average (range)
percentage of the dose excreted into the feces (primarily as furamidine
and one of the intermediate metabolites, M3) and urine (primarily as
M3) was 36% (33–40%) and 13% (11–16%), respectively. Extrapo-
lations of the data available after 168 h indicated that the average
(range) percentage of the dose excreted into the feces and urine would
be 39% (34–42%) and 13% (11–16%), respectively. There was
considerable retention of radioactivity (50% of the dose), largely as
furamidine, in the human body 7 days after [14C]pafuramidine
administration.
Whole-Body Human Semi-PBPK Model Prediction. Physiolog-
ical and pafuramidine/furamidine-specific parameters (Table 1) were
used to develop the human semi-PBPK model. No significant differ-
ence in plasma binding of pafuramidine and furamidine was observed
between rats and humans (Table 1). Furamidine unbound fraction in
human plasma (fu, p_F) was consistent with previously reported values
(24%) at concentrations ranging from 16 to 328 nM (Midgley et al.,
2007), indicating concentration-independent binding. Pafuramidine/
furamidine hepatic clearance values in humans were predicted by
scaling the corresponding in vivo rat values normalized by scaling
factors derived from rat and human SCH studies, as described under
Materials and Methods. Similar to rats, the renal clearance of fura-
midine from plasma (ClF_renal, u), estimated by the GFR approach,
was approximately 3-fold less than GFR (Table 1). Because a one-
compartment oral absorption model failed to predict the delayed
absorption of pafuramidine, transit compartments were added to the
human semi-PBPK model (Fig. 1B). The rate constants for pafurami-
dine absorption along the transit compartments (kP_12, kP_23, and
kP_3g) were similar (Table 1); the rate constant for pafuramidine
absorption from gut to liver (ka_P) was comparable to kP_12, kP_23, and
kP_3g but was 5-fold higher than that for furamidine absorption (ka_F)
(Table 1); and the rate constant for metabolic conversion of pafura-
midine to furamidine in the gut (kG_P3F) was approximately 4-fold
lower than ka_P (Table 1). The overall fraction of furamidine gener-
ated from pafuramidine in the gut and liver was approximately 50%;
similar to rats, the contribution by the liver was higher than that by the
gut (Table 3). Model predictions, based on the scheme depicted in Fig.
1B, adequately described pafuramidine and furamidine disposition
observed in plasma up to 24 h (Fig. 4A, inset). Prolonged (up to 240 h)
predictions indicated that the t1/2, terminal values of both pafuramidine
and furamidine were 1.5- and 4-fold longer, respectively, than those
measured from the 24-h observed in vivo data; the t1/2, terminal of
furamidine was 3-fold longer than that of pafuramidine (64 versus
19 h) (Fig. 4A). Similar to rats, the semi-PBPK model for human
disposition predicted that the liver and kidney are the major organs for
furamidine accumulation. Furamidine distribution between tissues
(liver and kidney) and plasma reached equilibrium after 36 h, as
reflected by the parallel terminal plasma concentration- and tissue
mass-time profiles (Fig. 4, A and B). Furamidine was eliminated in
humans primarily by biliary excretion; renal excretion was negligible
(Table 3; Fig. 4B).
Prediction of Dose-Exposure Relationship. The human semi-
PBPK model (Fig. 1B) was used to simulate plasma and liver time
profiles associated with various pafuramidine oral dosing regimens.
On the basis of the predefined hypothetical efficacy and safety indi-
ces, a regimen (40 mg once daily for 14 days) that maintained
furamidine plasma concentrations above the Ceff, min for 99% of the
time throughout the 14 days was selected (Fig. 5). On the basis of the
predicted plasma t1/2, terminal of furamidine, plasma concentrations of
furamidine reached steady-state at approximately 12 to 13 days;
Css, ave was approximately 4-fold higher than the Ceff, min and was
4-fold lower than the hypothetical NOAEL (Fig. 5). Predicted fura-
midine liver exposure, expressed as the area under the liver concen-
tration-time curve (AUC0–14 d), was 5-fold lower with this alternate
dosage regimen compared with the dosage regimen administered in
the expanded phase I safety study (100 mg twice daily for 14 days)
(Fig. 5); a similar trend also was observed with furamidine kidney
exposure between the two dosage regimens (data not shown).
Discussion
Accurate prediction of the pharmacokinetics of generated active
metabolites in humans is essential in the selection of appropriate
FIG. 4. Disposition of pafuramidine () and furamidine (Œ) in healthy male
subjects administered a single oral dose of [14C]pafuramidine maleate [nominal dose
131.9 mg, equivalent to 100 mg (274 mol) pafuramidine free base] in capsule
form. A, comparison of observed (symbols) and semi-PBPK model-predicted
(scheme depicted in Fig. 1B) (lines) plasma concentration-time profiles of pafura-
midine and furamidine over 24 h (inset) and 240 h. Symbols and error bars denote
mean values and SD, respectively, of six subjects. B, semi-PBPK model-predicted
(scheme depicted in Fig. 1B) amount versus time profiles of furamidine in liver/
kidney (solid lines) and bile/urine (dashed lines) over 240 h.
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prodrug doses before clinical trials. Pafuramidine is a prodrug of the
antiparasitic agent, furamidine, which demonstrated efficacy in ani-
mal models of first-stage human African trypanosomiasis (Mdachi et
al., 2009; Wenzler et al., 2009). Dose selection for antiparasitic drug
development traditionally has relied on achieving efficacious plasma
drug concentrations in humans that correlate with those in animal
models. A similar strategy was applied to pafuramidine, only plasma
concentrations of furamidine were correlated between species. The
current work represents the first attempt to optimize this prodrug
dose-selection strategy using whole-body semi-PBPK models for rats
and humans to predict plasma and tissue exposure and excretion
profiles of the active metabolite. Preclinical and clinical data gener-
ated during pafuramidine development were used as a training set to
demonstrate the utility of PBPK modeling to examine the relationship
between pafuramidine dose and furamidine plasma/tissue exposure,
which could be used to guide clinical dose-ranging studies of next-
in-class compounds.
The final model structure and pafuramidine absorption character-
istics in rats were used initially to predict pafuramidine and furami-
dine disposition in humans. However, the model prediction underes-
timated the Cmax and Tmax of pafuramidine and furamidine, which
possibly could be attributed to differences in dosage formulation
(suspension versus capsule) or concomitant diet (standard versus
high-fat meal) between rats and humans. Either of these factors could
increase the Cmax and Tmax of pafuramidine/furamidine in humans. As
such, transit compartments were added incrementally to the pafura-
midine human submodel; three transit compartments best described
pafuramidine absorption. Pafuramidine is a Biopharmaceutics Classi-
fication System class II compound (Zhou et al., 2002); the high-fat
meal was administered intentionally to facilitate pafuramidine absorp-
tion (Wu and Benet, 2005). This food effect was substantiated by the
enhanced fa estimated from the human compared with that from the rat
semi-PBPK model (Table 1). These observations emphasized that
formulation/diet may be a significant determinant of pafuramidine/
furamidine disposition.
Tissue-to-plasma partitioning (Kp) is another factor that influences
the disposition of compounds in the body. The in vivo Kp values for
pafuramidine and furamidine were not available for human tissues.
Unbound Kp values in rats and humans were assumed to be similar
(Kp, u, rat  Kp, u, human) (Arundel, 1997). Because no significant spe-
cies difference in plasma binding of pafuramidine/furamidine was
observed (Table 1), Kp values derived from the rat model were applied
to describe the distribution of pafuramidine/furamidine in humans.
Extrapolation of metabolite kinetics from animals to humans re-
mains a major challenge in PBPK modeling. Disposition of furami-
dine in the liver involves formation from pafuramidine, hepatocellular
binding, basolateral efflux/reuptake, and biliary excretion. Empirical
allometric scaling and physiologically based direct scaling were not
used because of 1) marked species differences in pafuramidine me-
tabolism (Table 2), 2) physiologically based direct scaling using rat
SCH underestimated metabolic Cl of pafuramidine in rat IPLs, and
3) in vitro biliary Cl of furamidine was too small to measure in rat and
human SCH (Table 2) (Yan et al., 2011). Normalized scaling via
integration of IPL and SCH data was used in the current work,
because this method successfully predicted hepatic metabolic Cl of 10
extensively metabolized drugs in humans (Lave et al., 1997). In
addition, incorporation of Cl, predicted by normalized scaling using
conventionally cultured hepatocytes, into the PBPK model of an
antimalarial drug, epiroprim, provided more accurate predictions of
epiroprim disposition in humans (Luttringer et al., 2003). SCH, rather
than conventionally cultured hepatocytes, were used in the current
study because of their ability to characterize both sinusoidal/biliary
transport and metabolism (Swift et al., 2010). The human semi-PBPK
model, based on these scaled parameters, adequately described pa-
furamidine/furamidine concentration-time profiles in human plasma
and predicted the dose-plasma/tissue exposure relationship and excre-
tion profiles (Fig. 4). To the authors’ knowledge, the current work
represents the first effort to extrapolate metabolism/transport clear-
ance from rats to humans for a prodrug/active metabolite pair.
Previous studies in rats and monkeys indicated that pafuramidine
has a low oral bioavailability (10–20%) (Midgley et al., 2007),
suggesting that pafuramidine could undergo extensive first-pass bio-
transformation in the gut, as well as in the liver. One report examined
pafuramidine metabolism in the gut; the intrinsic formation clearance
of the first intermediate metabolite (M1) from pafuramidine in human
intestinal microsomes was at least 10-fold lower than that in human
liver microsomes (Wang et al., 2007). As such, the liver was assumed
initially to be the sole site of furamidine formation. However, in vivo
studies showed a near-simultaneous appearance of furamidine with
pafuramidine in plasma in both rats and humans (Figs. 3A and 4A,
insets). Initial model predictions showed a marked delay in the ap-
pearance of furamidine relative to pafuramidine. This discrepancy
suggested that furamidine may be formed during pafuramidine ab-
sorption through the gut before entering the liver. Bioconversion of
pafuramidine to furamidine involves sequential oxidative and reduc-
tive reactions mediated by cytochrome P450 enzymes and cytochrome
b5/NADH cytochrome b5 reductases (Saulter et al., 2005; Wang et al.,
FIG. 5. Semi-PBPK model-predicted (scheme depicted in Fig. 1B) plasma and liver
concentration-time profiles of furamidine in humans after oral administration of 100
mg of pafuramidine free base twice daily (gray lines) and 40 mg of pafuramidine
free base once daily (black lines). Dotted and dashed lines represent safety and
efficacy indices defined by a hypothetic NOAEL and a minimum effective concen-
tration (Ceff, min) of furamidine in plasma, respectively. NOAEL and Ceff, min were
determined as described under Materials and Methods. Time  Ceff, min denotes the
time that furamidine concentrations in plasma were above the Ceff, min as a percent-
age of the entire dosing period (14 days), Css, ave denotes average plasma concen-
tration of furamidine at steady state, and “AUC0–14 d2 5x” denotes liver exposure
of furamidine, expressed as the area under the liver concentration-time curve
(AUC0–14 d), which was 5-fold lower with the modified pafuramidine dosage
regimen (40 mg once daily) compared with the dosage regimen administered in
the expanded phase I safety study (100 mg twice daily). The fold-difference in
furamidine exposure in the kidney between the two dosage regimens was similar to
that in the liver. The kidney profile is not shown because of near overlap with the
liver profile, reducing visual clarity. Note that furamidine plasma concentrations
under the modified dosage regimen reach a plateau in approximately 12 to 13 days;
the time to reach steady state appears shorter because of the log scale applied to the
y-axis.
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2006). These enzymes are expressed in both the liver and gut. Previ-
ous studies demonstrated that CYP4F, a major catalyst of M1 forma-
tion, represented a significant portion of the human intestinal P450
“pie” (Wang et al., 2007). These observations prompted incorporation
of a gut compartment, representing furamidine formation during pa-
furamidine absorption, in the furamidine rat/human submodel (Fig.
1B). The model described furamidine plasma disposition adequately
(Figs. 3A and 4A, insets). Concordant with in vivo observations, the
model predicted that, once absorbed, pafuramidine was converted
efficiently to furamidine in rats and humans, as reflected by nearly
50% conversion from pafuramidine; the gut contributed approxi-
mately 30 to 40% to furamidine formation in both species (Table 3).
These data suggested that the gut contributes significantly to furami-
dine formation after pafuramidine administration and substantiated
the value of PBPK modeling to uncover potentially important biolog-
ical determinants of drug disposition. In addition to formulation/diet
differences, the delayed appearance of furamidine in humans may also
reveal species differences in gut metabolism/transport. Further studies
are warranted to confirm that the gut is a major presystemic site of
furamidine formation after oral administration of pafuramidine and to
elucidate species differences in furamidine disposition in the gut.
In rats and humans administered a single oral dose of pafuramidine,
the t1/2, app of furamidine was approximately 4 and 14.5 h, respec-
tively, similar to that of pafuramidine (Figs. 3A and 4A, insets).
However, 1 week after [14C]pafuramidine administration, a consider-
able amount of radioactivity was retained in rats (Midgley et al., 2007)
and humans, largely as furamidine. According to pharmacokinetic
principles, the t1/2, terminal of a drug in plasma will equal that in the
tissues once the drug reaches distributional equilibrium. If furamidine
is assumed to comply with classic pharmacokinetic behavior at the
pafuramidine doses examined, the observed plasma profile of furami-
dine (Figs. 3A and 4A, insets) may represent the distribution, rather
than terminal, phase. Because of LC-MS/MS assay sensitivity limi-
tations in the current study, furamidine was below the limit of quan-
tification in plasma beyond 8 and 24 h after pafuramidine admi-
nistration to rats and humans, respectively. In the absence of a more
sensitive assay, the “true” t1/2, terminal of furamidine was predicted
using semi-PBPK modeling. The model predicted that furamidine
t1/2, terminal in rats was approximately 40-fold longer than t1/2, app (7
days versus 4 h). After intravenous administration of preformed
furamidine (10 mol/kg) to rats, furamidine was detected in the
kidney for up to 16 days. The corresponding kidney t1/2, terminal was
estimated to be 7 days (Goldsmith, 2011). The human plasma and
tissue t1/2, terminal of furamidine was predicted to be 64 h (2.5 days),
demonstrating the utility of PBPK modeling to estimate long-term
plasma and tissue exposure, which may not be possible to measure
directly in vivo because of analytical sensitivity and/or inaccessibility
to sampling sites such as the liver/kidney.
A semi-PBPK modeling approach was used in the current work to
examine the relationship between dose and plasma/tissue exposure for
an antiparasitic prodrug/active metabolite pair in humans. The model
predicted that the Css, ave of the active metabolite, furamidine, was
25-fold higher than the estimated Ceff, min in plasma (Fig. 5) based on
the dose administered (100 mg twice daily) in the expanded phase I
trial. This clinical dosage regimen triggered elevated liver transami-
nases in 25% of the subjects (Paine et al., 2010). An alternate dosage
regimen (40 mg once daily) was predicted to maintain furamidine
plasma concentrations half-way between the predefined hypothetical
efficacy and safety indices 99% of the time throughout the entire
14-day dosing period (Fig. 5), while reducing furamidine hepatic
exposure (Fig. 5). Model predictions suggested that if a patient were
to inadvertently miss or double the projected dose, only modest
fluctuations in plasma furamidine concentrations within the efficacy
safety range would result. Next-in-class compounds in development
for both stages of HAT are under investigation (Wenzler et al., 2009).
This semi-PBPK modeling-based approach, which requires in vitro/in
vivo data on metabolism, transport, and plasma/tissue binding, as well
as estimated/known efficacy (e.g., Ceff, min) and safety (e.g., NO-
AEL) indices, could be applied to next-in-class compounds to
predict plasma/tissue disposition and guide dose-ranging studies in
humans.
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Atissue/compartment amount in whole organ or compartment
AA amount in arterial blood
CA arterial blood concentration
CV venous blood concentration
CVP venous plasma concentration
B/P blood/plasma ratio
CVtissue vascular tissue concentration
Ctissue tissue concentration
CO cardiac output
Qtissue tissue blood flow
Vtissue tissue volume
Kp, tissue tissue-to-plasma partition coefficient
kP_12, kP_23, kP_3g first-order rate constants for pafuramidine distribution
along the transit compartments of gut
ka_P, ka_F first-order rate constants for the movement from gut
to liver of pafuramidine and formed furamidine,
respectively
kG_P3F first-order rate constant for metabolic conversion from
pafuramidine to furamidine in the gut
fu, L, fu, p unbound fractions in liver and plasma, respectively
ClL_P3F, u hepatic unbound intrinsic clearance for the formation
of furamidine from pafuramidine
ClL_P3M, u hepatic unbound intrinsic clearance for metabolic
conversion from pafuramidine to other metabolites
ClF_up, u unbound intrinsic clearance for hepatic basolateral
uptake of furamidine
ClF_eff, u unbound intrinsic clearance for hepatic basolateral
efflux of furamidine
ClF_bile, u unbound intrinsic clearance for biliary excretion of
furamidine
ClF_renal, u unbound renal clearance of furamidine from plasma
Rabs_P rate of pafuramidine movement from gut to liver
Rabs_F rate of intestinally formed furamidine movement from
gut to liver
Rgut formation_F rate of furamidine formation in the gut
Rliver formation_F rate of furamidine formation in the liver
Rliver formation_M rate of other metabolite formation in the liver
Rrenal_F rate of furamidine renal excretion
Rbile_F rate of furamidine biliary excretion
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Note: The volume of tissue and vascular blood in the liver represents
95 and 5%, respectively, of total liver volume (Nong et al., 2008). P,
pafuramidine; F, furamidine; M, other metabolites.
Human Semi-PBPK Model Equations
Pafuramidine
Disposition in the gut
1. Amount in transit compartment 1 (T1):
Single dose: dAT1/dt  (kp_12  AT1)  fa  Doral (t  0);
Multiple dose: dAT1/dt  (kp_12  AT1)  fa  Doral (at the
beginning of each dosing interval)
2. Amount in transit compartment 2 (T2):
dAT2/dt  (kp_12  AT1)  (kp_23  AT2)
3. Amount in transit compartment 3 (T3):
dAT3/dt  (kp_23  AT2)  (kp_3g  AT3)
4. Amount in the gut:
dAgut_P/dt  (kp_3g  AT3)  Rabs_P  Rgut formation_F
Rabs_P  ka_P  Agut_P
Rgut formation_F  kG_P3F  Agut_P
Disposition in the liver (flow-limited)
dAliver_P/dt  Qliver  (CAP  CVliver_P)  Rliver formation_F
 Rliver formation_M  Rabs_P
Cliver_P  Aliver_P/Vliver
CVliver_P  Cliver_P/Kp_liver_P
Rliver formation_F  Cliver_P  fu,L_P  ClL_P3F, u
Rliver formation_M  Cliver_P  fu,L_P  ClL_P3M, u
Disposition in the fat (flow-limited)
dAfat_P/dt  Qfat  (CAP  CVfat_P)
Cfat_P  Afat_P/Vfat
CVfat_P  Cfat_P/Kp_fat_P
Disposition in the rest of body (rest) (flow-limited)
dArest_P/dt  Qrest  (CAP  CVrest_P)
Crest_P  Arest_P/Vrest
CVrest_P  Crest_P/Kp_rest_P
Blood and plasma concentration
1. Venous blood concentration:
CVP  (Qliver  CVliver_P  Qfat  CVfat_P  Qrest  CVrest_P)/CO
2. Venous plasma concentration:
CVPP  CVP/(B/PP)
3. Arterial blood concentration:
dAAP/dt  QC  (CVP  CAP)
CAP  AAP/Vblood
Furamidine
Disposition in the gut
dAgut_F/dt  Rgut formation_F  Rabs_F
Rabs_F  ka_F  Agut_F
Disposition in the liver (diffusion-limited)
1. Liver blood:
dAVliver_F/dt  Qliver  (CAF  CVliver_F)  Rabs_P  Ruptake_F 
Refflux_F
CVliver_F  AVliver_F/(0.05  Vliver)
2. Liver tissue:
dAliver_F/dt  Rliver formation_F  Ruptake_F  Refflux_F  Rbile_F
Cliver_F  Aliver_F/(0.95  Vliver)
Ruptake_F  CVliver_F  fu,p_F  ClF_up, u
Refflux_F  Cliver_F  fu,L_F  ClF_eff, u
Rbile_F  Cliver_F  fu,L_F  ClF_bile, u
Disposition in the kidney (flow-limited)
dAkidney_F/dt  Qkidney  (CAF  CVkidney_F)
Ckidney_F  Akidney_F/Vkidney
CVkidney_F  Ckidney_F/Kp,kidney_F
Disposition in the rest of body (rest) (flow-limited)
dArest_F/dt  Qrest  (CAF  CVrest_F)
Crest_F  Arest_F/Vrest
CVrest_F  Crest_F/Kp,rest_F
Blood and plasma concentration
1. Venous blood concentration:
CVF  (Qliver  CVliver_F  Qkidney  CVkidney_F  Qrest 
CVrest_F)/CO
2. Venous plasma concentration:
CVPF  CVF/(B/PF)
3. Arterial blood concentration:
dAAF/dt  QC  (CVF  CAF)  Rrenal_F
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